These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19147774)

  • 1. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
    Morgan TM; Lange PH; Porter MP; Lin DW; Ellis WJ; Gallaher IS; Vessella RL
    Clin Cancer Res; 2009 Jan; 15(2):677-83. PubMed ID: 19147774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.
    Shikanov S; Song J; Royce C; Al-Ahmadie H; Zorn K; Steinberg G; Zagaja G; Shalhav A; Eggener S
    J Urol; 2009 Jul; 182(1):139-44. PubMed ID: 19450829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
    Chalfin HJ; Glavaris SA; Malihi PD; Sperger JM; Gorin MA; Lu C; Goodwin CR; Chen Y; Caruso EA; Dumpit R; Kuhn P; Lang JM; Nelson PS; Luo J; Pienta KJ
    J Urol; 2018 Jun; 199(6):1494-1501. PubMed ID: 29339080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
    Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
    Urol Res; 1999 Aug; 27(4):285-90. PubMed ID: 10460901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer.
    Todenhöfer T; Hennenlotter J; Faber F; Wallwiener D; Schilling D; Kühs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Fehm T; Stenzl A; Schwentner C
    Prostate; 2015 May; 75(6):637-45. PubMed ID: 25586166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
    Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
    J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.